News - Lipitor, Markets & Marketing

Filter

Popular Filters

$30 billion of fresh opportunities for Rx-to-OTC switch in USA

19-02-2013

The US Food and Drug Administration has recently created the Non-prescription Safe Use Regulatory Expansion…

LipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRegulation

Mylan starts selling generic Lipitor in Europe; to buy back shares

14-05-2012

US generic drug major Mylan's (Nasdaq: MYL) shares 2.2% to $21.55 in morning last Friday after the company…

atorvastatinCardio-vascularEuropeFinancialGenericsLipitorMarkets & MarketingMylan Laboratories

Ranbaxy debuts generic Lipitor in Germany, ahead of patent expiry

07-03-2012

The German subsidiary of India's Ranbaxy Laboratories (AB: BO), Basics GmbH located in Leverkusen, yesterday…

atorvastatinBasics GmbHCardio-vascularDaiichi SankyoEuropeGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

Lipitor and strategic collapse at Pfizer, a consultants view

05-01-2012

Now global pharma behemoth Pfizer (NYSE: PFE) spent $114 billion in 2000 for a hostile takeover of Warner-Lambert,…

Cardio-vascularFinancialLipitorMarkets & MarketingPfizerPharmaceutical

Payers’ outlook for Pfizer’s Lipitor generic strategy not rosy; second Caduet copy launched by Ranbaxy

06-12-2011

Reimbursement Intelligence, a USA-based market-research firm, has announced how payers predict the impact…

CaduetCardio-vascularGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

US launch of generic Lipitor confirms value of competition, says GPhA

01-12-2011

Commenting on this week’s US roll out for generic copies of Pfizer blockbuster cholesterol lowerer…

GenericsLipitorMarkets & MarketingNorth AmericaPatentsPfizerRanbaxy LaboratoriesWatson Pharmaceuticals

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top